Trav12n-1 Inhibitors
Trav12n-1 inhibitors are a class of chemical compounds that specifically target the Trav12n-1 protein or receptor, modulating its biological function by inhibiting its activity. These inhibitors typically operate by binding to the active site of the Trav12n-1 protein, preventing the interaction between the protein and its natural ligands or substrates. This competitive binding blocks the protein's normal role in biochemical processes. In addition to active-site binding, some Trav12n-1 inhibitors may also bind to allosteric sites, which are regions separate from the active site. When bound to these allosteric sites, the inhibitors induce conformational changes that disrupt the protein's structure and reduce or completely inhibit its activity. These interactions between the Trav12n-1 inhibitors and the protein are mediated by a variety of non-covalent forces, including hydrogen bonding, van der Waals interactions, hydrophobic effects, and ionic interactions, which together contribute to the stability and specificity of the inhibitor-protein complex.
The chemical structure of Trav12n-1 inhibitors can be highly diverse, with designs ranging from small organic molecules to larger, more complex frameworks. These inhibitors often feature aromatic rings, heterocyclic structures, and key functional groups such as hydroxyl, carboxyl, or amine groups, which enhance their ability to interact with specific regions of the Trav12n-1 protein. These functional groups enable important non-covalent interactions, such as hydrogen bonding or hydrophobic interactions, that stabilize the binding of the inhibitor within the protein's active or allosteric site. Additionally, the design of these inhibitors takes into account various physicochemical properties, such as molecular weight, lipophilicity, polarity, and solubility. Hydrophobic regions in the inhibitor structure may interact with non-polar regions of the protein, while polar or charged functional groups can form electrostatic or hydrogen-bonding interactions with polar residues. This balance of hydrophilic and hydrophobic properties is crucial for optimizing the binding affinity and stability of Trav12n-1 inhibitors in different biological environments, allowing for efficient modulation of the protein's function.
SEE ALSO...
Items 1 to 10 of 20 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate competitively inhibits dihydrofolate reductase (DHFR), an enzyme involved in tetrahydrofolate synthesis. Tetrahydrofolate is necessary for the synthesis of purines and pyrimidines, which are precursors of nucleic acids. As a component of the adaptive immune response, Trav12n-1 is likely to be required for the proliferation of immune cells that rely on nucleotide synthesis. Inhibition of DHFR by Methotrexate would therefore result in reduced proliferation of these cells, indirectly inhibiting the functional activity of Trav12n-1. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A inhibits calcineurin, which is essential for the activation of T-lymphocytes. By inhibiting calcineurin, Cyclosporin A prevents the dephosphorylation and activation of nuclear factor of activated T-cells (NFAT), a transcription factor required for T-cell activation. Since Trav12n-1 is involved in T-cell receptor (TCR) diversity and T-cell activation, the inhibition of T-cell activation by Cyclosporin A would indirectly inhibit the functional activity of Trav12n-1 in the immune response. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the resulting complex inhibits the mechanistic target of rapamycin (mTOR), a kinase involved in cell cycle progression and proliferation. The inhibition of mTOR decreases T-cell proliferation and differentiation, thus indirectly inhibiting the functional activity of Trav12n-1, given its role in T-cell function. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
FK506, also known as Tacrolimus, binds to FKBP and inhibits calcineurin, similarly to Cyclosporin A. By inhibiting calcineurin, FK506 suppresses T-cell activation and interleukin-2 production. Since Trav12n-1 is part of the T-cell receptor complex, its functional activity is indirectly inhibited by the suppression of T-cell activation that FK506 induces. | ||||||
Sulfasalazine | 599-79-1 | sc-204312 sc-204312A sc-204312B sc-204312C | 1 g 2.5 g 5 g 10 g | $61.00 $77.00 $128.00 $209.00 | 8 | |
Sulfasalazine inhibits the transcription factor NF-κB, which is involved in the immune response, including the activation and proliferation of T-cells. By inhibiting NF-κB, Sulfasalazine may indirectly inhibit the functional activity of Trav12n-1 by reducing T-cell proliferation and function. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide exerts immunomodulatory effects, including the inhibition of T cell co-stimulation and modulation of cytokine production. By altering T-cell dynamics and responses, Lenalidomide indirectly inhibits the functional activity of Trav12n-1, which is involved in the T-cell receptor complex. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $57.00 | 1 | |
Hydroxychloroquine can inhibit the activation of Toll-like receptors (TLRs) on plasmacytoid dendritic cells, which is a key step in the innate immune response and subsequent activation of the adaptive immune response. By inhibiting TLR signaling, hydroxychloroquine can reduce activation of T-cells, thereby indirectly inhibiting the functional activity of Trav12n-1. | ||||||
Azathioprine | 446-86-6 | sc-210853D sc-210853 sc-210853A sc-210853B sc-210853C | 500 mg 1 g 2 g 5 g 10 g | $203.00 $176.00 $349.00 $505.00 $704.00 | 1 | |
Azathioprine is metabolized into 6-mercaptopurine which inhibits purine synthesis, crucial for DNA replication. This inhibition can reduce T-cell and B-cell proliferation, thereby indirectly inhibiting the functional activity of Trav12n-1 by limiting the proliferation of T-cells that would express Trav12n-1. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine interferes with lysosomal acidification, which can affect antigen presentation in immune cells. By altering antigen presentation, Chloroquine can decrease T-cell activation, thereby indirectly inhibiting the functional activity of Trav12n-1 which would be involved in T-cell receptor signaling. | ||||||
Mycophenolate mofetil | 128794-94-5 | sc-200971 sc-200971A | 20 mg 100 mg | $37.00 $109.00 | 1 | |
Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase, | ||||||